Clinical trials: Tislelizumab
Esophageal Squamous Cell Carcinoma
Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
The goal of this observational study was to explore the safety and efficacy of short course hypofractionated radiotherapy combined with Raltitrexed and Tislelizumab in the treatment of patients with relapsed or advanced…
- Trial name
- SCHRT (NCT06408584)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Anhui Provincial Hospital
HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with high tumor burden advanced-stage hepatocellular…
- Conditions
- HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma, Lenvatinib
- Trial name
- NCT06631326
- Testing
- hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 244 people
- Sponsor
- First Hospital of China Medical University
PD-1 Antibody, DC-Cell
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
This is a prospective, open, single-arm Phase II clinical study to evaluate the efficacy and safety of anti-PD-1 antibody combined with autologous DC and NK cells in the treatment of digestive carcinoma.
- Conditions
- PD-1 Antibody, DC-Cell, NK-Cell, Gastrointestinal Tumours
- Trial name
- NCT05461235
- Testing
- Pembrolizumab, Nivolumab, Sintilimab
- Volunteers
- 1 people
- Sponsor
- China Medical University, China
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
This was an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of surzebiclimab (BGB-A425) and/or alcestobart (LBL-007) with tislelizumab.
- Conditions
- Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- Trial name
- NCT03744468
- Testing
- Surzebiclimab, Tislelizumab, Alcestobart
- Where
- 40 sites in United States, Australia and 4 more
- Volunteers
- 147 people
- Sponsor
- BeiGene
Advanced Solid Tumor
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab (Part 1) or tislelizumab (Part 2) in the…
- Trial name
- NCT05547321
- Testing
- OMTX705, Pembrolizumab, Tislelizumab (BGB-A317)
- Where
- 9 sites in United States, Spain
- Volunteers
- 150 people
- Sponsor
- Oncomatryx Biopharma S.L.
Locally Advanced Rectal Cancer
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
This is an open, prospective, multi-center, single-arm phase II clinical study assessing the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin in patients with pMMR/MSS locally…
- Trial name
- NCT06056804
- Testing
- capecitabine, tislelizumab, thymalfasin
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Gastric Cancer
Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore
This is a single-arm, open-label, multi-center clinical study to evaluate the efficacy and safety of PD-1/CTLA-4 bispecific cadonilimab in combination with oxaliplatin/capecitabine (CapeOX) in the first-line treatment of advanced…
- Trial name
- NCT06202716
- Testing
- Cadonilimab plus CapeOX chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Unresectable Non-small Cell Lung Cancer
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
This is a prospective, single-arm, multicenter, phase II clinical study designed to evaluate the initial efficacy and safety of patients receiving Tislelizumab in combination with recombinant human endostatin injection plus…
- Trial name
- NCT06617936
- Testing
- neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy, surgery, Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hua Zhang
Biliary Tract Carcinoma
GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC
This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of GP (Gemcitabine/Cisplatin) in combination with Tislelizumab and Ociperlimab as first-line treatment in participants with unresectable…
- Trial name
- NCT05023109
- Testing
- GP+PD-1+Tight
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Minimal Residual Disease, Adjuvant Chemotherapy
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have "positive" ctDNA tests for MRD (meaning there is evidence of MRD based on this…
- Conditions
- Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib
- Trial name
- NCT07136077
- Testing
- Tislelizumab, Fruquintinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer Stage III
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
The goal of this randomized, controlled phase III clinical trial is to evaluate whether combining Tislelizumab with standard SOX chemotherapy improves disease-free survival (DFS) compared to chemotherapy alone in patients with…
- Trial name
- NCT06939439
- Testing
- Tislelizumab + SOX Chemotherapy, SOX Chemotherapy
- Where
- China
- Volunteers
- 416 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Melanoma
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus lenvatinib in patients with melanoma liver metastasis.
- Trial name
- NCT05406466
- Testing
- Tislelizumab, Lenvatinib, Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Oligodendroglioma
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
This is an ongoing Phase 2, open-label, single-center, non-randomized study of sintilimab (one anti-PD-1 antibody same as nivolumab approved in China) plus bevacizumab administered in a low dosage schedule in adult (≥ 18 years)…
- Trial name
- NCT05512351
- Testing
- Tislelizumab plus Bevacizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Henan Provincial People's Hospital
Esophageal Squamous Cell Carcinoma
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
Esophageal cancer is one of the most common malignancies in China, and esophageal squamous cell carcinoma (ESCC) is the predominant histological type.
- Trial name
- NCT05984342
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
Head and Neck Cancer, Radiation
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study
To investigate whether concurrent Tislelizumab with postoperative chemoradiotherapy would have survival benefit in high Risk HNSCC Patients.
- Conditions
- Head and Neck Cancer, Radiation, PD-1
- Trial name
- NCT04814069
- Testing
- Tislelizumab
- Volunteers
- 38 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
The purpose of study is to investigate the safety and efficacy of sequential immunotherapy with neoadjuvant chemoradiotherapy for esophageal cancer
- Trial name
- CRIS (NCT06303583)
- Testing
- paclitaxel, carboplatin, tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qiu Guoqin
Resectable Hepatocellular Carcinoma
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is a prospective, one-arm, phase II clinical study of Tislelizumab combined with Lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.
- Trial name
- NCT04834986
- Testing
- Tislelizumab combined with Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC
Safety and Efficacy of NK510 to Treat NSCLC
This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural…
- Trial name
- NCT06097962
- Testing
- NK510, Tislelizumab，atezolizumab or sugemalimab, systemic therapy as selected by the investigator
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Colo-rectal Cancer
A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases
To explore the Efficacy and Safety of Tislelizumab combined with fruquintinib and Chidamide in the treatment of unresectable or advanced microsatellite stabilized (MSS/pMMR) colorectal cancer with liver metastases
- Trial name
- NCT06218888
- Testing
- Tislelizumab, Fruquintinib, Chidamide
- Volunteers
- 17 people
- Sponsor
- Fujian Cancer Hospital
Glioblastoma
Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.
To investigate the efficacy, safety and tolerability of superselective cerebral arterial infusion of Bevacizumab combined with intrathecal injection of Tislelizumab in the treatment of recurrent glioblastoma
- Trial name
- NCT05811793
- Testing
- Tislelizumab and Bevacizumab
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital of Nanchang University